Cytokinetics Inc Investor Event Transcript
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics Conference Call. At this time, I would like to inform you that this call is being recorded. (Operator Instructions) I would now like to turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Good morning, everyone, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will begin with an overview of today's announcement and next steps related to omecamtiv mecarbil. Then we'll open the call to questions, and Robert will be joined by Fady Malik, Executive Vice President of R&D; Libby Schnieders, Senior Vice President of Business Development; Ching Jaw, Senior Vice President and Chief Financial Officer; and Mark Schlossberg, Senior Vice President, Legal & General Counsel.
Please note that portions of the following discussion, including our responses to questions, contain
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |